

**NEW ORLEANS BIOINNOVATION CENTER, INC.  
AND SUBSIDIARY**

**CONSOLIDATED FINANCIAL STATEMENTS**

**June 30, 2021**

**NEW ORLEANS BIOINNOVATION CENTER, INC.  
AND SUBSIDIARY**

**TABLE OF CONTENTS**

	<b>Pages</b>
INDEPENDENT AUDITORS' REPORT	3
CONSOLIDATED FINANCIAL STATEMENTS	
Consolidated Statement of Financial Position	5
Consolidated Statement of Activities	6
Consolidated Statement of Cash Flows	7
Notes to Consolidated Financial Statements	8
SUPPLEMENTARY INFORMATION	
Schedule of Compensation, Benefits, and Other Payments to Agency Head	18
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government     Auditing Standards</i>	19
Schedule of Findings and Responses	21
Schedule of Prior Audit Findings	22



Carr, Riggs & Ingram, LLC  
111 Veterans Boulevard  
Suite 350  
Metairie, LA 70005  
  
504.837.9116  
504.837.0123 (fax)  
CRIcpa.com

## **INDEPENDENT AUDITORS' REPORT**

Board of Directors of  
New Orleans BioInnovation Center, Inc. and Subsidiary  
New Orleans, Louisiana

We have audited the accompanying consolidated financial statements of New Orleans BioInnovation Center, Inc. and Subsidiary (the Corporation), which comprise the consolidated statement of financial position as of June 30, 2021, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

### **Management's Responsibility for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditors' Responsibility**

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Corporation's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Corporation as of June 30, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

## Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplemental information listed in the table of contents on page 18 is presented for purposes of additional analysis and is not a required part of the basic consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements taken as a whole.

## Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated March 25, 2022, on our consideration of New Orleans BioInnovation Center, Inc. and Subsidiary's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of New Orleans BioInnovation Center, Inc. and Subsidiary's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering New Orleans BioInnovation Center, Inc. and Subsidiary's internal control over financial reporting and compliance.

*Carr, Riggs & Ingram, L.L.C.*

Metairie, Louisiana  
March 25, 2022

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS OF JUNE 30, 2021**

	<b>2021</b>
<b>ASSETS</b>	
Cash and cash equivalents	\$ 956,467
Accounts and other receivables—net	627,139
Notes receivable—net	65,822
Investments	-
Prepaid expenses and other assets	158,142
Property, plant, and equipment—net	35,195,467
<b>TOTAL ASSETS</b>	<b>\$ 37,003,037</b>
<b>LIABILITIES AND NET ASSETS</b>	
<b>LIABILITIES:</b>	
Accounts payable and accrued liabilities	\$ 160,916
Rental deposits	72,192
Refundable advance - Paycheck Protection Program	118,832
Deferred revenue	371,264
Total liabilities	723,204
<b>NET ASSETS:</b>	
Without donor restrictions	1,114,562
With donor restrictions	\$ 35,165,271
Total net assets	36,279,833
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>\$ 37,003,037</b>

The accompanying notes are an integral part of the consolidated financial statements.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**

**CONSOLIDATED STATEMENT OF ACTIVITIES  
FOR THE YEAR ENDED JUNE 30, 2021**

	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total 2021</b>
<b>REVENUES:</b>			
Government grants and contracts	\$1,006,458	\$ -	\$ 1,006,458
Public support	5	-	5
Contributed services	199,638	-	199,638
Rental income	1,280,311	-	1,280,311
Other	97,549	-	97,549
Net assets released from restrictions	1,131,185	(1,131,185)	-
<b>Total revenues</b>	<b>3,715,146</b>	<b>(1,131,185)</b>	<b>2,583,961</b>
<b>EXPENSES:</b>			
Salaries and related expenses	579,615	-	579,615
Contract outside services	238,375	-	238,375
Professional services	62,124	-	62,124
Supplies	45,976	-	45,976
Telecommunications	42,243	-	42,243
Postage and shipping	118	-	118
Printing and copying	130	-	130
Books, subscriptions, reference	3,369	-	3,369
Rent	9,606	-	9,606
Utilities	321,317	-	321,317
Equipment rental and maintenance	150,735	-	150,735
Travel and meeting expenses	8,200	-	8,200
Insurance	120,663	-	120,663
Membership dues	6,050	-	6,050
Outside computer services	16,942	-	16,942
Marketing expense	31,580	-	31,580
Contributed services expense	199,638	-	199,638
Loss on investments	145,379	-	145,379
Bad debts	13,950	-	13,950
Other costs	2,095	-	2,095
<b>Total expenses</b>	<b>1,998,105</b>	<b>-</b>	<b>1,998,105</b>
Change in net assets from operating activities before depreciation	1,717,041	(1,131,185)	585,856
Depreciation	1,144,572	-	1,144,572
<b>CHANGE IN NET ASSETS</b>	<b>572,469</b>	<b>(1,131,185)</b>	<b>(558,716)</b>
<b>BEGINNING NET ASSETS</b>	<b>542,093</b>	<b>36,296,456</b>	<b>36,838,549</b>
<b>ENDING NET ASSETS</b>	<b>\$1,114,562</b>	<b>\$ 35,165,271</b>	<b>\$ 36,279,833</b>

The accompanying notes are an integral part of the consolidated financial statements.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**

**CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED JUNE 30, 2021**

	<b>2021</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>	
Change in net assets	\$ (558,716)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:	
Depreciation and amortization	1,144,572
Provision for bad debts	13,950
Loss on investments	145,379
Changes in operating assets and liabilities:	
Increase in accounts and other receivables	(178,640)
Increase in prepaid expenses and other assets	(1,855)
Decrease in accounts payable	(22,523)
Increase in deferred revenue and rental deposits	77,329
Net cash provided by operating activities	\$ 619,496
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>	
Purchase of investments	\$ (145,379)
Proceeds from collections of notes receivable	239,258
Purchase of property, plant and equipment	(49,258)
Net cash provided by investing activities	\$ 44,621
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>664,117</b>
<b>CASH AND CASH EQUIVALENTS—Beginning of year</b>	<b>292,350</b>
<b>CASH AND CASH EQUIVALENTS—End of year</b>	<b>\$ 956,467</b>

The accompany notes are an integral part of the consolidated financial statements.



**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE A - SUMMARY OF ACCOUNTING POLICIES**

A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows.

**1. Principles of Consolidation**

The consolidated financial statements include the accounts of New Orleans BioInnovation Center, Inc. (NOBIC) and its wholly owned subsidiary, New Orleans BioFunding, L.L.C., (NOBF), a for-profit corporation. All inter-company accounts and transactions have been eliminated. At June 30, 2021, an intercompany payable of \$675,700 was due from NOBIC to NOBF.

**2. Nature of Activities**

The New Orleans BioInnovation Center, Inc. and Subsidiary (the "Corporation") is a business incubator, with the primary purpose of creating and supporting jobs, primarily in the bioscience and environmental science areas. This mission is supported by a leasing office and wet-lab space and providing free or low-cost business services to local life science start-up companies. The Corporation also periodically holds public business coaching seminars/workshops provided by members of the business community. In addition, the Corporation supplies capital to emerging companies in the Greater New Orleans area in the form of loans and equity investments. The Corporation's activities are intended to foster economic development through the creation of new jobs, diversification of the local economy, and revitalization of an economically depressed area of the City of New Orleans. It is located in its 66,000 square foot facility located at 1441 Canal Street in downtown New Orleans.

The Corporation may also develop and manage other properties within the bio-medical corridor.

The Corporation is a private, non-profit entity. The Corporation is organized and shall be operated for the principal purpose of supporting one or more programs, facilities or research or educational opportunities offered by Louisiana State University Health Sciences Center, Tulane University Health Sciences Center, Xavier University, the University of New Orleans, and the community at large.

The New Orleans BioInnovation Center, Inc. is organized and constituted as a nonprofit corporation exempt from income taxation under and in accordance with the provisions of Section 501 (c)(3) of the Internal Revenue Code and the Nonprofit Corporation Law of the State of Louisiana, La.Rev.Stat. 12:201-269.



**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE A - SUMMARY OF ACCOUNTING POLICIES - Continued**

**3. Financial Statement Presentation**

As prescribed by Accounting Standards Update (ASU) 2016-14, Presentation of Financial Statements of Not-for-Profit Entities (Topic 958), the corporation classifies its net assets into two categories: net assets without donor restrictions and net assets with donor restrictions.

The Corporation's two net asset categories are described below.

Net assets without donor restrictions include the following:

- Net assets without donor restrictions include funds not subject to donor-imposed stipulation or other restrictions and the net revenues received and expenses incurred in conducting its missions.

Net assets with donor restrictions include the following:

- Net assets with donor restrictions include funds for which donor-imposed restrictions have not been met, and as of June 30, 2021, consist of the original cost of the building and equipment, reduced by amortization over the depreciable life of the building.

**4. Revenue Recognition**

**Government Grants and Contracts** - Grants are recognized when NOBIC has reasonable assurance that (1) it has complied with the relevant conditions of the grant in the applicable reporting period, and (2) the grant funds will be received.

**Public Support** - NOBIC recognizes all contributed support as income in the period received. Contributed support is reported as without donor restriction or with donor restriction depending on the existence of donor stipulations that limit the use of the support. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restriction are reclassified to net assets without donor restriction and reported in the statement of activity as "net assets released from restrictions."

**Leases** - As a lessor, NOBIC has retained substantially all of the risks and benefits of ownership of properties held for lease and accounts for the leases as operating leases. Income on leases, which includes scheduled increases in rental rates during the lease term and/or abated rent payments for various periods following the tenant's lease commencement date, is recognized on the straight-line method over the life of the lease. Lease payments received in advance are recorded as deferred revenue.

**Contribution Revenue - Donated Services** - Donated services that meet the criteria for recognition as contributions consisting of contributed services that enhance nonfinancial assets or require specialized skill as support are recorded at their fair value. Fair value is estimated based on fees or hourly rates charged for similar services under similar conditions.

**5. Cash and Cash Equivalents**

For the purpose of the consolidated statement of cash flows, the Corporation considers all investments with original maturities of three months or less to be cash equivalents.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE A - SUMMARY OF ACCOUNTING POLICIES – Continued**

**6. Accounts and Other Receivables - net**

The Corporation carries an allowance for doubtful accounts of \$20,000 which management considers adequate. Management regularly assesses the adequacy of the allowance for doubtful accounts by evaluating the collectability of aging receivables, the past history of the tenant and other factors.

**7. Notes Receivable - net**

Notes are stated at the amount of unpaid principal, reduced by an allowance for note losses, discussed in Note A-8. Interest on the notes range from fixed rates of 6.0% to 6.75%.

Management reviews the note portfolio to determine the existence of, and extent to which there is any doubt regarding collectability.

**8. Provision and Allowance for Note Losses**

The consolidated financial statements are prepared in accordance with FASB ASC 310. The allowance for estimated note losses is maintained to provide for possible losses inherent in the note portfolio. Management determines the appropriate level of reserve to be maintained based on an analysis of the portfolio and evaluation of economic factors. Such factors as note growth, the future collectability of notes and the amounts and timing of future cash flows expected to be received on impaired notes are uncertain, therefore the level of future provisions generally cannot be predicted.

The balance of the note portfolio at June 30, 2021 was \$65,822, and the allowance for estimated note losses at June 30, 2021 was zero.

**9. Investments**

Investments are presented in accordance with requirements established by the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) as set forth in the FASB ASC 958-320, Investments-Debt and Equity Securities. Under FASB ASC 958-320, investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statement of financial position. Unrealized gains and losses are included in the change in net assets.

Dividends, interest and other investment income is recorded as increases in unrestricted net assets unless the use is restricted by the donor. Donated investments are recorded at fair value at the date of receipt.

**10. Property, Plant and Equipment- net**

The Corporation capitalizes at cost, all property, plant and equipment in excess of \$5,000. Lesser amounts are expensed as incurred. Depreciation is provided for in amounts sufficient to relate the costs of depreciable assets to operations over their estimated service lives or leasehold life, whichever is shorter, based on the straight-line method. A summary of the estimated useful lives assigned adopted by the Corporation are as follows:

	Estimated Useful Life
Buildings	40 years
Equipment	10 years

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE A - SUMMARY OF ACCOUNTING POLICIES – Continued**

The Corporation reviews long-lived assets for impairments whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset, an impairment loss is recognized. At June 30, 2021, management believes no such impairment has occurred.

**11. Fair Values of Financial Instruments**

Generally accepted accounting principles require disclosure of fair value information about financial instruments for which it is practicable to estimate fair value, whether or not recognized in the consolidated statement of financial position. Cash and cash equivalents carrying amounts reported in the consolidated statement of financial position approximate fair values because of the short maturities of those instruments. See additional fair value information in Note E.

**12. Refundable Advance – Paycheck Protection Program**

The Corporation is accounting for the Small Business Administration Paycheck Protection Program loan which is still pending forgiveness as a financial liability at June 30, 2021 following the guidance in accordance with FASB ASC 470.

**13. Advertising Costs**

The Corporation expenses advertising costs as incurred. Marketing expense was \$31,580 for the year ended June 30, 2021.

**14. Subsequent Events**

Management has evaluated subsequent events through the date that the consolidated financial statements were available to be issued, December 31, 2021. No subsequent events occurring after this date have been evaluated, except as noted in Note G below, for inclusion in these consolidated financial statements.

**15. Recently Issued Accounting Standards**

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. This accounting standard requires leases to recognize assets and liabilities related to lease arrangements longer than 12 months on the financial position as well as additional disclosures. For nonpublic entities, the standard is effective for fiscal years beginning after December 15, 2021. The Corporation is currently evaluating the impact of the guidance on its consolidated financial statements.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE B – MANAGED SERVICES AGREEMENT**

Effective March 1, 2020, NOBIC entered into a Managed Services Agreement with Tulane University (Tulane) to provide support through the use of its employees or independent contractors which includes the following areas at no cost to NOBIC: a) building operations and maintenance, b) property management and leasing, c) financial, accounting and bookkeeping services and d) other areas. The initial term of the agreement is for five years with five successive five-year automatic renewal periods, unless terminated in writing by either party in accordance with the provisions, as defined. Contributed service revenue recorded for the year ended June 30, 2021 for this agreement was \$199,638 in the consolidated statement of activities. Additionally, Tulane rented laboratory and office space in the amount of \$ 402,500 which is included in rental income in the consolidated statement of activities. Contributed services revenue is comprised of the following for the year ended June 30, 2021:

	<b>2021</b>
Contributed Financial Services	<b>\$ 156,600</b>
Contributed Operations and Maintenance Services	<b>39,438</b>
Contributed Information Technology	<b>3,600</b>
	<b>\$ 199,638</b>

**NOTE C – ACCOUNTS AND OTHER RECEIVABLES – NET**

Accounts and other receivables - net as of June 30, 2021 consisted of amounts due from the following sources:

	<b>2021</b>
Trade receivables	<b>\$ 5,000</b>
Rent receivable	<b>58,972</b>
Grants receivable	<b>479,314</b>
Interest and other receivable	<b>103,853</b>
Total accounts receivable	<b>\$ 647,139</b>
Less allowance for doubtful accounts	<b>(20,000)</b>
Accounts and other receivables, net	<b>\$ 627,139</b>

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE D – NOTES RECEIVABLE**

Notes receivable for the year ended July 30, 2021 totaled \$65,822. Future note payments for this note at July 30, 2021 were as follows:

<b>Fiscal Year</b>	<b>Amount</b>
2022	\$ 25,439
2023	25,439
2024	14,944
2025	-
2026	-
Total	<u>\$ 65,822</u>

**NOTE E – INVESTMENTS**

As of June 30, 2021, NOBF had investments consisting of preferred stock and convertible instruments, as follows:

Convertible promissory note	\$ 128,721
Preferred stock	530,035
Total	<u>658,756</u>
Valuation reserve	<u>(658,756)</u>
Total Investments	<u>\$ -</u>

Generally accepted accounting principles require that investments be presented at fair value. The investments are with companies in the initial stage of development and show the promise of growth in the local area. The companies are also working with the universities in New Orleans using university-based technology to develop viable products. Current year loss on investments in these companies is \$145,379 as noted in the consolidated statement of activities. The fair value of the investments in these companies is considered to be zero at June 30, 2021.

**NOTE F – PROPERTY, PLANT AND EQUIPMENT – NET**

Property and equipment consist of the following at June 30, 2021:

Building	\$ 45,247,408
Equipment	1,673,020
Total	<u>46,920,428</u>
Less accumulated depreciation	<u>(11,724,961)</u>
Property, plant and equipment, net	<u>\$ 35,195,467</u>

The building was constructed on land leased from Louisiana State University, which has a reversionary interest in the building. See Note I.

Depreciation expense for the year amounted to \$1,144,572.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE G– REFUNDABLE ADVANCE**

Refundable advance consists of a loan from the Paycheck Protection Program (PPP). In April 2020, in response to the global pandemic, the Corporation applied for and received a \$118,832 loan through the PPP under the CARES Act. In fiscal year 2021 the Corporation applied for forgiveness for the entire amount of the loan and all accrued interest. In July of fiscal year 2022 the SBA issued notice of forgiveness for the entirety of the loan and all accrued interest. The interest rate on the loan was a fixed rate of 1%. No interest or principal was due within the first six months after the loan amount was disbursed, although interest continued to accrue over this six-month deferral period. Accrued interest upon forgiveness receipt totaled \$1,479.

**NOTE H - DEFERRED REVENUE**

Deferred revenue consists of prepaid tenant rent and ACE Louisiana conference sponsorships of \$350,764 and \$20,500, respectively. Deferred revenue at June 30, 2021 totaled \$371,264.

**NOTE I - LEASE AGREEMENT**

Louisiana State University (LSU) owns the land located at 1441 Canal Street, New Orleans. NOBIC entered into a lease agreement with LSU on December 13, 2002 for a primary term of 20 years and options to renew the lease for two 10-year periods. Rental payments stated in the First Lease Amendment dated April 11, 2017, provides for \$800 a month commencing upon substantial completion of construction and acceptance for occupancy by NOBIC. The rental rates for renewal option periods provided for by the Renovation Lease shall be calculated by first determining the value of the land as follows: capitalizing the net operating income for the project for the year preceding the exercise of the option at ten percent, and attributing twenty percent of the value so derived to the land; and, second, applying, ten percent of the land value so determined as the annual rent for the renewal period. Louisiana State University has a reversionary interest in the building.

Rental expense for the year ended June 30, 2021 totaled \$9,606. Future minimum rental payments for this lease as of June 30, 2021 were as follows:

<b>Fiscal Year</b>	<b>Amount</b>
2022	\$ 9,600
2023	9,600
2024	9,600
2025	9,600
2026 and thereafter	<u>157,600</u>
Total	<u>\$ 196,000</u>

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE J - TENANT LEASES**

The Corporation leases office, laboratory and parking facilities to tenants under operating leases. The leases are for an initial term of one year, with an option to renew for various periods extending through 2031. Lease revenue for the year ended June 30, 2021 amounted to \$1,280,311. Future minimum rental payments on non-cancelable operating leases with lease terms in excess of one year as of June 30, 2021 were as follows:

<b>Fiscal Year</b>	<u><b>Amount</b></u>
2022	\$ 1,182,050
2023	798,686
2024	618,486
2025	244,396
2026 and thereafter	<u>-</u>
Total	<u><u>\$ 2,843,618</u></u>

**NOTE K - INCOME TAXES**

NOBIC is exempt from corporate income taxes under Section 501 (c)(3) of the Internal Revenue Code.

NOBIC has adopted the provision of FASB ASC 740-10-25, which requires a tax position be recognized or derecognized based on a "more likely than not" threshold. This applies to positions taken or expected to be taken in a tax return. The Corporation does not believe its financial statements include any uncertain tax positions.

The Corporation's wholly owned subsidiary, NOBF, has elected to be treated as a disregarded entity for income taxation purposes. All activity is therefore presented on the Corporation's tax return.



**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE L - FUNCTIONAL EXPENSES**

Expenses related to payroll, payroll taxes, and employee benefits are allocated based on actual percentages of time spent in each functional area. All other directly identifiable expenses are charged to programs and supporting services. The functional allocation of expenses as of June 30, 2021 is detailed below.

	<b>Business Services</b>	<b>Facilities</b>	<b>Loan Program</b>	<b>Management and General</b>	<b>Total</b>
Salaries and related expenses	\$ 210,636	\$ 120,330	\$ 151,385	\$ 97,264	\$ 579,615
Contract outside services	41,231	182,068	467	14,609	238,375
Professional services	32,288	-	7,764	22,072	62,124
Supplies	11,350	15,293	-	19,333	45,976
Telecommunications	-	39,396	-	2,847	42,243
Postage and shipping	-	-	-	118	118
Printing and copying	130	-	-	-	130
Books, subscriptions, reference	482	-	-	2,887	3,369
Rent	-	9,600	-	6	9,606
Utilities	-	321,317	-	-	321,317
Depreciation	-	1,144,572	-	-	1,144,572
Equipment rental and maintenance	4,381	140,447	-	5,907	150,735
Travel and meeting expenses	1,465	-	1,200	5,535	8,200
Insurance	-	120,663	-	-	120,663
Membership dues	3,550	-	2,500	-	6,050
Outside computer services	5,782	3,875	-	7,285	16,942
Marketing expense	31,168	-	-	412	31,580
Contributed services expense	-	39,438	-	160,200	199,638
Loss on investments	-	-	145,379	-	145,379
Provision for bad debts	-	13,950	-	-	13,950
Other costs	-	3	175	1,917	2,095
<b>Total</b>	<b>\$ 342,463</b>	<b>2,150,952</b>	<b>308,870</b>	<b>340,392</b>	<b>3,142,677</b>

**NOTE M – CONCENTRATIONS OF CREDIT RISK**

The Corporation maintains cash deposits with financial institutions at June 30, 2021 in excess of federally insured limits of \$479,108.

**NOTE N - RETIREMENT PLAN**

The Corporation sponsors a defined contribution plan. All full-time employees are eligible upon date of hire, however, participation is voluntary. The Corporation contributes to the plan an amount equal to 100% of the employee's contribution, limited to 3% of the employee's salary. The contribution rate remained unchanged from the prior year. The 401(k) employer match expense for the year ended June 30, 2021 amounted to \$9,928.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE O - NET ASSETS**

Net assets with and without donor restrictions at June 30, 2021 consist of the following:

	<b>2021</b>
Without donor restrictions- undesignated	<b>\$ 1,114,562</b>
With donor restrictions- purpose restricted original building and equipment	<b>35,066,742</b>
With donor restrictions- other	<b>98,529</b>
	<b>\$36,279,833</b>
Total net assets	<b>\$36,279,833</b>

During FY 2021, \$1,131,185 was released from restrictions, equivalent to the annual depreciation expense of the original building and equipment, whose use is restricted per the lease agreement with LSU (see Note H).

**NOTE P – LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS**

The Corporation maintains its financial assets primarily in cash and cash equivalents to provide liquidity to ensure funds are available as the Corporation’s expenditures come due. The following reflects the Corporation’s financial assets as of the statement of financial position date, reduced by amounts not available for general use within one year of the statement of financial position date because of contractual or donor-imposed restrictions.

	<b>June 30, 2021</b>
Total assets, at year end	<b>\$ 37,003,037</b>
Less nonfinancial assets:	
Property, plant and equipment—net	<b>(35,195,467)</b>
Prepaid expenses and other assets	<b>(158,142)</b>
	<b>\$ 1,649,428</b>
Less those unavailable for general expenditure within one year due to:	
Notes receivable beyond one year	<b>(40,383)</b>
Time-restrictions	<b>-</b>
	<b>\$ 1,609,045</b>

The Corporation is principally supported by its rental and grant income. In order to assist with meeting its cash flow requirements, the Corporation has a Cooperative Endeavor Agreement with the Louisiana Department of Economic Development which provides funding to support the Corporation’s mission and a Managed Services Agreement with Tulane University which provides contributed services (See Note B). The Cooperative Endeavor Agreement with the Louisiana Department of Economic Development ended December 31, 2021. As of December 31, 2021 the Cooperative Endeavor Agreement has not been renewed. Management is in the process of negotiating a renewal.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2021**

**NOTE R- BOARD OF DIRECTORS' COMPENSATION**

The Board of Directors is a voluntary board. Accordingly, no compensation was paid to any board member during the year ended June 30, 2021. An officer of Tulane University also serves on the Board of Directors of NOBIC (See Note B).

**NOTE S- UNCERTAINTIES**

In March 2020, the World Health Organization made the assessment that the outbreak of a novel coronavirus (COVID-19) can be characterized as a pandemic. As a result, uncertainties have arisen that may have a significant negative impact on the operating activities and results of the Corporation. The occurrence and extent of such an impact will depend on future developments, including (i) the duration and spread of the virus, (ii) government quarantine measures, (iii) voluntary and precautionary restrictions on travel or meetings, (iv) the effects on the financial markets, and (v) the effects on the economy overall, all of which are uncertain.

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY  
SCHEDULE OF COMPENSATION, BENEFITS AND OTHER PAYMENTS  
TO AGENCY HEAD**

**Agency Head Name: Kristopher Khalil, President**

The Agency Head is Kristopher Khalil, President, New Orleans BioInnovation Center, Inc. and Subsidiary did not make any payments with public funds to or on behalf of the President for the year ended June 30, 2021.

**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

Board of Directors of  
New Orleans BioInnovation Center, Inc. and Subsidiary  
New Orleans, Louisiana

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of New Orleans BioInnovation Center, Inc. and Subsidiary (the Corporation), which comprise the consolidated statement of financial position as of June 30, 2021, and the related statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated March 25, 2022.

**Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the Corporation's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Corporation's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

## **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Corporation's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

## **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Carr, Riggs & Ingram, L.L.C.*

Metairie, Louisiana  
March 25, 2022

**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY  
SCHEDULE OF FINDINGS AND RESPONSES  
JUNE 30, 2021**

**SECTION I – SUMMARY OF AUDITORS’ REPORTS**

***Financial Statements***

- |  |            |
|--|------------|
| 1. Type of auditors’ report issued:  | Unmodified |
| 2. Internal controls over financial reporting:                                   |            |
| a. Material weakness identified?   | None noted |
| b. Significant deficiencies identified not considered to be a material weakness? | None noted |
| c. Noncompliance material to financial statements noted?                         | None noted |

**SECTION II – FINANCIAL STATEMENTS FINDINGS**

No findings noted.



**NEW ORLEANS BIOINNOVATION CENTER, INC. AND SUBSIDIARY  
SCHEDULE OF PRIOR AUDIT FINDINGS  
JUNE 30, 2021**

**SECTION II – FINANCIAL STATEMENTS FINDINGS**

No findings noted.